NASDAQ · Biotechnology · USD
NewcelX Ltd. (NCEL) Stock Analysis
NewcelX Ltd. (NCEL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
NCEL Key Statistics
As of Oct 21, 2026Trading
- Open
- $2.59
- Previous Close
- $2.61
- Day's Range
- 2.59–3.04
- 52-Week Range
- 1.83–16.60
- Volume
- 11.93K
Valuation
- Market Cap
- $17.04M
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$8.30M
- Shares Outstanding
- 5.78M
- 1-Year Return
- −82.54%
Dividend and dates
- Avg Volume
- 8.42K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, NCEL closed at $2.95, −82.54% over 1 year.
NewcelX Ltd. (NCEL) has a market capitalization of $17.04M.
In fiscal 2025, NCEL reported revenue of $0.00.
NCEL Stock Return by Calendar Year
NewcelX Ltd. (NCEL) return since Jan 2021: what $10,000 became
- 1 year
- $10,000 $1,746
- −82.54%
- 5 years
- $10,000 $31
- −99.69%
- Since Jan 2021
- $10,000 $26
- −99.74%
If you had invested $10,000 in NewcelX Ltd. (NCEL) at the close on January 29, 2021, the earliest close on record here, it would have been worth $26 at the close on October 21, 2026: −99.74% in total, −64.76% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +55.26% |
| 2025 | −91.00% |
| 2024 | −91.06% |
| 2023 | −54.26% |
| 2022 | +16.22% |
| 2021 | −61.59% |
As of October 21, 2026.
NCEL Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$8.30M | — |
| 2024 | $0.00 | −$7.20M | — |
| 2023 | $0.00 | −$3.33M | — |
| 2022 | $0.00 | −$6.45M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$2.47M | −$8.30M | — |
| 2024 | $0.00 | $0.00 | −$1.80M | −$7.20M | — |
| 2023 | $0.00 | $0.00 | −$3.02M | −$3.33M | — |
| 2022 | $0.00 | $0.00 | −$6.25M | −$6.45M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B